pSivida (NSDQ:PSDV) is looking to market its Durasert 3-year treatment for posterior segment uveitis in the European Union. Today, the Watertown, Mass.-based company submitted a marketing authorization application to the European Medicines Agency.
Earlier this month, pSivida reported that its 2nd Phase III trial, which followed patients for 3 years, met its primary endpoint of prevention of recurrence of posterior uveitis at 6 months.
Get the full story at our sister site, Drug Delivery Business News.
The post pSivida seeks European regulatory nod for Durasert appeared first on MassDevice.
from MassDevice http://ift.tt/2sUHtvh
Cap comentari:
Publica un comentari a l'entrada